Skip to Content
MilliporeSigma
All Photos(1)

Documents

SML2215

Sigma-Aldrich

Aprepitant

≥98% (HPLC)

Synonym(s):

Aprepitant, 3H-1,2,4-Triazol-3-one, 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro, 5-[[(2R,3S)-2-[(1R)-1-[3,5bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3one, Emend, L-754030, MK 869, MK-0869, ONO 7436, 3-[[(2R,3S)-2-[(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholino]methyl]-1H-1,2,4-triazol-5(4H)-one, 5-[[(2R,3S)-2-[(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C23H21F7N4O3
CAS Number:
170729-80-3
Molecular Weight:
534.43
MDL number:
MFCD12912491
UNSPSC Code:
12352200
NACRES:
NA.77

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D +61 to +71°, c = 1.0 in methanol

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

SMILES string

FC1=CC=C([C@@H]([C@@H](O[C@H](C)C2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2)OCC3)N3CC4=NNC(N4)=O)C=C1

InChI

1S/C23H21F7N4O3/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)37-20-19(13-2-4-17(24)5-3-13)34(6-7-36-20)11-18-31-21(35)33-32-18/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H2,31,32,33,35)/t12-,19-,20+/m1/s1

InChI key

ATALOFNDEOCMKK-BYYRLHKVSA-N

Looking for similar products? Visit Product Comparison Guide

Application

Aprepitant has been used as neurokinin 1 (NK1) receptor antagonist in dorsal root ganglion (DRG) derived cells and bone marrow mesenchymal stem cells (BMSCs) coculture.

Biochem/physiol Actions

Aprepitant is an antiemetic drug. It is a moderate cytochrome P450 3A4 (CYP3A4) inhibitor. It is capable of crossing the blood brain barrier in humans. In animals, aprepitant can cross the placental barrier. Aprepitant is a potent and selective antagonist of human substance P/neurokinin 1 (NK1) receptors used clinically to treat chemotherapy-induced or post-operative nausea and vomiting, and being investigated for other activity including possible treatment for depression and pruritis.

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 4

1 of 4

Palbociclib ≥98% (HPLC)

Sigma-Aldrich

PZ0383

Palbociclib

Ketoconazole 99.0-101.0% (EP, titration)

Sigma-Aldrich

K1003

Ketoconazole

Azithromycin dihydrate ≥98% (HPLC)

Sigma-Aldrich

PZ0007

Azithromycin dihydrate

Corning® Costar® Transwell® cell culture inserts TC treated, PET membrane, diam. 6.5 mm, pore size 8.0 μm, sterile

CLS3464

Corning® Costar® Transwell® cell culture inserts

Sergei Spitsin et al.
JCI insight, 2(19) (2017-10-06)
HIV-infected individuals, even well controlled with combined antiretroviral therapy (cART), have systemic inflammation and comorbidities. Substance P (SP) is an undecapeptide, which mediates neurotransmission and inflammation through its cognate neurokinin 1 receptor (NK1R). Plasma SP levels are elevated in HIV-infected
Aprepitant: A substance P antagonist for chemotherapy induced nausea and vomiting
Girish C, et al.
Indian Journal of Cancer, 44(1), 25-25 (2007)
Alice He et al.
BioMed research international, 2017, 4790810-4790810 (2017-10-24)
Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and
Aprepitant and fosaprepitant drug interactions: a systematic review
Patel P, et al.
British Journal of Clinical Pharmacology, 83(10), 2148-2148 (2017)
Deepti Jacob et al.
American journal of physiology. Gastrointestinal and liver physiology, 313(5), G505-G510 (2017-08-18)
Aprepitant, an NK1 receptor antagonist, is approved for the treatment of chemotherapy-induced or postoperative emesis by blocking NK1 receptors in the brain stem vomiting center. The effects of NK1 receptors on gastric functions and postprandial symptoms in humans are unclear;
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service